MA26672A1 - Compositions pharmaceutiques contenant un inhibiteur de lipases gastro-intestinales, un (ou plusieurs) compose(s) supplémentaire(s) du groupe constitué par le chitosane, ses dérivés et ses sels, et des excipients auxiliaires - Google Patents

Compositions pharmaceutiques contenant un inhibiteur de lipases gastro-intestinales, un (ou plusieurs) compose(s) supplémentaire(s) du groupe constitué par le chitosane, ses dérivés et ses sels, et des excipients auxiliaires

Info

Publication number
MA26672A1
MA26672A1 MA25726A MA25726A MA26672A1 MA 26672 A1 MA26672 A1 MA 26672A1 MA 25726 A MA25726 A MA 25726A MA 25726 A MA25726 A MA 25726A MA 26672 A1 MA26672 A1 MA 26672A1
Authority
MA
Morocco
Prior art keywords
chitosane
derivatives
salts
group
pharmaceutical compositions
Prior art date
Application number
MA25726A
Other languages
English (en)
Inventor
Bailly Jacques
Hadvary Paul
Lengsfeld Hans
Fleury Andre
Steffen Hans
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26672A1 publication Critical patent/MA26672A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
MA25726A 1998-08-14 1999-08-11 Compositions pharmaceutiques contenant un inhibiteur de lipases gastro-intestinales, un (ou plusieurs) compose(s) supplémentaire(s) du groupe constitué par le chitosane, ses dérivés et ses sels, et des excipients auxiliaires MA26672A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98115310 1998-08-14
EP99109430 1999-05-11

Publications (1)

Publication Number Publication Date
MA26672A1 true MA26672A1 (fr) 2004-12-20

Family

ID=26149536

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25726A MA26672A1 (fr) 1998-08-14 1999-08-11 Compositions pharmaceutiques contenant un inhibiteur de lipases gastro-intestinales, un (ou plusieurs) compose(s) supplémentaire(s) du groupe constitué par le chitosane, ses dérivés et ses sels, et des excipients auxiliaires

Country Status (20)

Country Link
US (1) US6030953A (fr)
EP (1) EP1105123B1 (fr)
JP (1) JP3761783B2 (fr)
KR (1) KR20010079636A (fr)
CN (1) CN1152680C (fr)
AR (1) AR034691A1 (fr)
AT (1) ATE263558T1 (fr)
AU (1) AU759388B2 (fr)
BR (1) BR9912979B1 (fr)
CA (1) CA2340052C (fr)
CO (1) CO5160286A1 (fr)
DE (1) DE69916288T2 (fr)
DK (1) DK1105123T3 (fr)
ES (1) ES2217797T3 (fr)
MA (1) MA26672A1 (fr)
PE (1) PE20000954A1 (fr)
PT (1) PT1105123E (fr)
TR (1) TR200100472T2 (fr)
WO (1) WO2000009123A1 (fr)
ZA (1) ZA200100690B (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264937B1 (en) * 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
KR20010079636A (ko) * 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 라이페이즈 저해제 및 키토산을 포함하는 약학 조성물
US6607749B1 (en) 1998-09-08 2003-08-19 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US6235305B1 (en) * 1999-10-29 2001-05-22 2Pro Chemical Essentially nonabsorbable lipase inhibitor derivatives, pharmaceutical compositions and methods of use therefor
EP1132389A1 (fr) 2000-03-06 2001-09-12 Vernalis Research Limited Nouveaux dérivés de l'azaindole pour le traitement de l'obésité
FI20000780A (fi) * 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
EP1142572A1 (fr) * 2000-04-04 2001-10-10 Volker Dr. Helmstädter Composés contenant de l'oxetanon destinés au traitement des maladies intestinales
JP4549486B2 (ja) * 2000-04-26 2010-09-22 アピ株式会社 抗肥満薬及びその製造方法
EP1296656B1 (fr) 2000-06-27 2006-08-02 F. Hoffmann-La Roche Ag Procede de preparation de composition
MEP90508A (en) 2000-07-28 2011-12-20 New pharmaceutical composition
AU2001289696B2 (en) 2000-07-28 2006-07-06 Cheplapharm Arzneimittel Gmbh New use of lipase inhibitors
PT1311260E (pt) 2000-08-09 2008-05-02 Hoffmann La Roche Utilização de inibidores de lipase para o tratamento da dispepsia
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US6251421B1 (en) * 2000-09-25 2001-06-26 Sarfaraz K. Niazi Pharmaceutical composition containing psyllium fiber and a lipase inhibitor
BR0114708A (pt) 2000-10-16 2003-07-01 Hoffmann La Roche Compostos, composições farmacêuticas que compreendem os mesmos, utilização dos compostos, processo de tratamento de distúrbios e de obesidade, e processos para a preparação dos compostos e de uma composição
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
CA2432085C (fr) 2000-12-27 2009-02-24 F. Hoffmann-La Roche Ag Derives d'indole et leur utilisation en tant que ligands de recepteurs 5-ht2b et 5-ht2c
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
US20030072804A1 (en) * 2001-03-19 2003-04-17 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
US20030091610A1 (en) * 2001-03-19 2003-05-15 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
WO2002094789A1 (fr) 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Derives de la quinoleine utilises comme ligands pour le recepteur y de neuropeptide
WO2002099123A1 (fr) * 2001-06-05 2002-12-12 The Children's Hospital Of Philadelphia Procedes et trousses pour diagnostiquer un trouble de malabsorption de graisses associe au pancreas
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US7049345B2 (en) * 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
EP1474145B1 (fr) 2002-02-04 2008-04-23 F. Hoffmann-La Roche Ag Derives de quinoline en tant qu'antagonistes du neuropeptide (npy)
US20040091450A1 (en) * 2002-02-26 2004-05-13 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
WO2003072577A1 (fr) 2002-02-28 2003-09-04 F.Hoffmann-La Roche Ag Derives thiazoles utilises comme antagonistes du recepteur npy
ATE453390T1 (de) * 2002-04-26 2010-01-15 Hoffmann La Roche Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
JP2005535648A (ja) 2002-07-05 2005-11-24 エフ．ホフマン−ラ　ロシュ　アーゲー キナゾリン誘導体
MXPA05001328A (es) 2002-08-07 2005-04-28 Hoffmann La Roche Derivados de tiazol.
ES2209632B1 (es) * 2002-08-30 2005-08-01 Romildo Holding, N.V. Complemento dietetico, soluble, efervescente y alimenticio.
CN100577660C (zh) 2002-09-12 2010-01-06 霍夫曼-拉罗奇有限公司 作为ppar激动剂用于治疗糖尿病的n-取代-1h-吲哚-5-丙酸化合物
DE10248575A1 (de) * 2002-10-17 2004-05-06 Christian-Albrechts-Universität Zu Kiel Chiltosanpellets
PL377320A1 (pl) 2002-11-25 2006-01-23 F. Hoffmann-La Roche Ag Pochodne indolilowe
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
GB0310919D0 (en) * 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
DE602004019939D1 (de) 2003-08-12 2009-04-23 Hoffmann La Roche Thiazolderivate als npy-antagonisten
DE602004010529T2 (de) 2003-08-12 2008-11-27 F. Hoffmann-La Roche Ag 2-amino-5-benzoylthiazol npy-antagonisten
US20080075688A1 (en) * 2003-10-31 2008-03-27 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
JP2005154477A (ja) * 2003-11-20 2005-06-16 Tottori Univ 紫外線硬化型キトサン誘導体を用いた医療用接着剤および医療用被覆剤
AU2004318688A1 (en) * 2004-03-23 2005-11-03 Lytone Enterprise, Inc. Chitosan embedded or encapsulated capsule
US7465417B2 (en) * 2004-07-19 2008-12-16 Baxter International Inc. Parametric injection molding system and method
MXPA04010692A (es) * 2004-10-28 2006-05-02 Jorge Luis Rosado Loria Composicion para el tratamiento de la obesidad e hiperlipidemia.
ITMI20050150A1 (it) * 2005-02-03 2006-08-04 Umberto Cornelli Prodotti alimentari
EP1888585B1 (fr) 2005-05-03 2011-06-29 F. Hoffmann-La Roche AG Azapyrazinoindolines tetracycliques constituant des ligands 5-ht2
MX2008002061A (es) 2005-08-18 2008-04-16 Hoffmann La Roche Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
ES2359739T3 (es) 2005-11-30 2011-05-26 F. Hoffmann-La Roche Ag Derivados de indol-2-il-amida 1,5-sustituida.
BRPI0619233A2 (pt) 2005-11-30 2011-09-20 Hoffmann La Roche compostos, processo para a sua manufatura, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal
ATE507222T1 (de) 2005-11-30 2011-05-15 Hoffmann La Roche 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren
ES2333672T3 (es) 2005-12-09 2010-02-25 F. Hoffmann-La Roche Ag Derivados de amida triciclica para tratamiento de obesidad.
AU2006326135A1 (en) 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-c]pyridine derivatives
KR101015666B1 (ko) 2005-12-16 2011-02-22 에프. 호프만-라 로슈 아게 Ｈ3 수용체 조절제로서 피롤로[2,3-ｂ]피리딘 유도체
ITMI20060384A1 (it) * 2006-03-03 2007-09-04 Umberto Cornelli Composizioni comprendenti chitosano atte al trattamento terapeutico complessivo o alla prevenzione complessiva della sindrome metabolica
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
BRPI0711740A2 (pt) 2006-05-30 2011-12-06 Hoffmann La Roche compostos, processo para a sua manufatura,composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, método para o tratamento ou prevenção de obesidade, de diabetes do tipo ii, e uso dos compostos na manufatura de medicamentos
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
TR200607613A2 (tr) * 2006-12-29 2008-07-21 NOBEL İLAÇ SAN.ve TiC.A.Ş. Lipaz inhibitörü içeren farmasötik formülasyonlar
EP2016946B1 (fr) * 2007-07-18 2013-02-27 The Jordanian Pharmaceutical Manufacturing Co. Composition de coprécipité de chitosane et de dioxyde de silicium pour une utilisation en tant qu'agent thérapeutique
KR20100027231A (ko) 2007-07-25 2010-03-10 에프. 호프만-라 로슈 아게 벤조퓨란- 및 벤조[ｂ]티오펜-2-카복실산 아마이드 유도체 및 이의 히스타민 3 수용체 조절제로서의 용도
WO2012070702A1 (fr) * 2010-11-25 2012-05-31 주식회사 삼양사 Composition contenant de l'orlistat et du chitosane et son procédé de préparation
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
CN105520947B (zh) * 2015-12-24 2018-05-01 广东药科大学 一种含有氨基葡萄糖的具有减肥功能的药物组合物
JOP20180128A1 (ar) * 2018-12-24 2020-06-24 Univ Of Petra صيغة دوائية صلبة قابلة للتشتت في الفم
GB202212379D0 (en) * 2022-08-25 2022-10-12 GlaxoSmithKline Consumer Healthcare UK IP Ltd Novel toothpaste tablet composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223023A (en) * 1978-10-12 1980-09-16 Ivan Furda Nonabsorbable lipid binder
CA1247547A (fr) * 1983-06-22 1988-12-28 Paul Hadvary Derives de leucine
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
CA2098167C (fr) * 1992-06-24 2006-12-19 Dorothea Isler Aliments pour humains et animaux contenant un inhibiteur de la lipase
KR20010079636A (ko) * 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 라이페이즈 저해제 및 키토산을 포함하는 약학 조성물

Also Published As

Publication number Publication date
JP3761783B2 (ja) 2006-03-29
DE69916288D1 (de) 2004-05-13
ZA200100690B (en) 2002-06-26
US6030953A (en) 2000-02-29
DE69916288T2 (de) 2005-03-24
ATE263558T1 (de) 2004-04-15
CA2340052C (fr) 2007-05-29
AU759388B2 (en) 2003-04-10
CN1152680C (zh) 2004-06-09
EP1105123B1 (fr) 2004-04-07
JP2002522492A (ja) 2002-07-23
CA2340052A1 (fr) 2000-02-24
AU5420599A (en) 2000-03-06
WO2000009123A1 (fr) 2000-02-24
AR034691A1 (es) 2004-03-17
KR20010079636A (ko) 2001-08-22
PE20000954A1 (es) 2000-09-27
ES2217797T3 (es) 2004-11-01
CN1312714A (zh) 2001-09-12
TR200100472T2 (tr) 2001-07-23
CO5160286A1 (es) 2002-05-30
PT1105123E (pt) 2004-08-31
DK1105123T3 (da) 2004-08-09
BR9912979B1 (pt) 2010-09-21
EP1105123A1 (fr) 2001-06-13
BR9912979A (pt) 2001-05-08

Similar Documents

Publication Publication Date Title
MA26672A1 (fr) Compositions pharmaceutiques contenant un inhibiteur de lipases gastro-intestinales, un (ou plusieurs) compose(s) supplémentaire(s) du groupe constitué par le chitosane, ses dérivés et ses sels, et des excipients auxiliaires
CA2340056A1 (fr) Compositions pharmaceutiques comportant des inhibiteurs de lipase
LU91563I2 (fr) Combinaisson comprenant de l'aliskiren, comme baselibre ou comme un de ses sels pharmaceutiquement acceptables, et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables-Rasilez HCT
DZ2614A1 (fr) Compositions pharmaceutiques topiques contenant des dérivés de résorcinol.
ITRM990338A0 (it) Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria.
AU2001264595A1 (en) Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
HUP0000839A2 (hu) Ciklosporint és egy anionos felületaktív szert tartalmazó szilárd gyógyszerkészítmények és eljárás ezek előállítására
AU7449598A (en) Medicinal composition for prevention or treatment of hepatopathy
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
HUP0103575A3 (en) Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use
CA2348086A1 (fr) Formulations pharmaceutiques a liberation controlee
BG103425A (en) Pharmaceutical composition
DZ2594A1 (fr) Dérivés de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant.
PT1177195E (pt) 1-amino-triazolo¬4,3-a|quinazolina-5-onas e/ou -5-tionas inibidoras de fosfodiesterases iv
WO2000066104A3 (fr) Composes inhibant ace-2 et leurs procedes d'utilisation
CA2359354A1 (fr) Medicament pour le traitement, la prevention et le diagnostic d'une infection due a chlamydia pneumoniae
CA2261040A1 (fr) Compositions medicinales
BR9610842A (pt) Composição farmacêutica compreendendo um inibidor de proteinase e um monoglicerídeo
MA26486A1 (fr) Aryl- et heteroaryl-thiazolocetohydrazides inhibiteurs de proteases, et compositions pharmaceutiques les contenant .
NO980296D0 (no) Forbedrede terapeutiske midler
PL328916A1 (en) Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs
MA26540A1 (fr) Composes nouveaux inhibiteurs de proteases et compositions pharmaceutiques les contenant.
AU2961199A (en) Hiv cofactor inhibitors and medicinal compositions for preventing or treating hiv-infection
AU4980400A (en) Compositions and methods for detection of active proteases
FR2768338B1 (fr) Compositions pharmaceutiques contenant un inhibiteur de la monoamine oxydase et leur application en therapeutique